Coronavirus Update: Regeneron's REGEN-COV Authorized For Prevention
Executive Summary
Regeneron's antibody cocktail gets emergency authorization for post-exposure prophylaxis from the US FDA. Daewoong's camostat shows efficacy in older patients in South Korean trial.
You may also be interested in...
Coronavirus Update: With New Data, Don’t Count J&J Out Yet
J&J announced strong data for its single-shot vaccine, with even stronger booster shot data to boot. Also Gilead posted strong results for outpatient use of Veklury, but it faces stiff competition, while Clover announced new data and Pfizer/BioNTech sold another 500 million vaccine doses for donation.
Antibody COVID-19 Therapies Back in China Spotlight Amid Infection Surge
Chinese developers forge ahead with research into antibody therapies for COVID-19 as coronavirus variants gain a toe-hold in the country.
Regeneron Follows REGEN-COV Revenue Success With Impressive PD-1 Data
Regeneron reported $2.76bn in revenues from the sale of its COVID-19 antibody cocktail, and that Libtayo in combo with chemotherapy was effective in NSCLC.